PharmaTher Obtains FDA Meeting for Ketamine Drug Application
PharmaTher Holdings Ltd., a specialty pharmaceutical company, has reported an important development in its efforts to address the ketamine shortage in the United States. The company has requested and received approval for a post-complete response letter clarification meeting with the FDA. This request comes after the FDA issued a complete response letter (CRL) related to PharmaTher's Abbreviated New Drug Application (ANDA) for ketamine. The FDA assigned a goal date for this submission under the Generic Drug User Fee Amendments of 2022 (GDUFA) that was originally set for late October.
Key Meeting Details and Implications
Scheduled for late November, this meeting will address deficiencies noted in the CRL that the FDA considers minor. It's crucial for PharmaTher to ensure that its responses will align with the expectations set forth by the FDA, leaving no room for error. The company plans to announce a new date for the meeting soon and will present a timeline for resubmission following the discussion. Ensuring a thorough approach demonstrates PharmaTher's commitment to meeting regulatory standards.
Understanding the Complete Response Letter
The CRL highlighted that specific information and clarifications were required related to aspects such as drug substance, drug product, manufacturing processes, and microbiological controls. Notably, the FDA has indicated it has no concerns regarding the stability of ketamine batches, which has demonstrated an impressive stability of 18 months. Additionally, no new preclinical or clinical studies were mandated for this application, a significant relief for the company.
PharmaTher's Commitment to Addressing Ketamine Shortage
Addressing the ongoing ketamine shortage in the U.S. is at the forefront of PharmaTher's mission. The company is dedicated to complying with FDA manufacturing guidelines while ensuring that ketamine is available for those in need. Since early 2018, ketamine has been listed as a critical shortage, prompting the proliferation of compounded products that lack FDA approval, particularly for psychiatric disorders. Such products have caused concern, especially as highlighted in recent risk alerts regarding these compounded ketamine solutions.
The Importance of FDA Approval
Having ketamine on the FDA's essential medicines list underscores its role in medical treatments for anesthesia and pain relief. Health Canada has already approved this drug for sedative use in clinical settings. Beyond its established uses, ketamine is also being explored for its potential in treating various mental health conditions, with encouraging results from recent peer-reviewed studies showing positive effects on conditions like depression, anxiety, and suicidal ideation.
About PharmaTher Holdings Ltd.
PharmaTher Holdings Ltd. is committed to developing and commercializing innovative treatments, particularly through its flagship product, KETARX™. The company also holds a significant stake in Sairiyo Therapeutics Inc., which is advancing novel formulations for viral infectious diseases. With a focus on addressing glaring medical needs, PharmaTher seeks to reshape the landscape of therapeutic options available in the market.
Contact Information
For additional information about PharmaTher Holdings Ltd., interested parties can reach out via the following contacts:
Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com
Frequently Asked Questions
What is the recent FDA meeting about?
The FDA meeting aims to clarify the complete response letter related to PharmaTher's ketamine Abbreviated New Drug Application.
What was the outcome of the FDA's complete response letter?
The CRL classified the noted deficiencies as minor, which PharmaTher plans to address in the upcoming meeting.
Why is ketamine important in medical treatments?
Ketamine is listed as a critical drug for anesthesia and pain relief, making it essential for various medical procedures.
What risks are associated with compounded ketamine products?
Compounded ketamine products may not meet FDA standards, raising concerns about safety and efficacy, especially for psychiatric use.
How is PharmaTher addressing the ketamine shortage?
PharmaTher is committed to resolving the ketamine shortage and is working on regulatory compliance to ensure product availability.
